ABO-505
Autosomal Dominant Optic Atrophy (ADOA)
PreclinicalActive
Key Facts
Indication
Autosomal Dominant Optic Atrophy (ADOA)
Phase
Preclinical
Status
Active
Company
About Abeona Therapeutics
Abeona Therapeutics is dedicated to delivering transformative cell and gene therapies for patients with severe rare diseases. The company has achieved a significant milestone with the commercial launch of ZEVASKYN® and maintains a diverse pipeline spanning preclinical to Phase 1/2 development, primarily targeting inherited retinal diseases and neurological conditions. Its strategy is supported by in-house manufacturing capabilities at The Elisa Linton Center for Rare Disease Therapies and key partnerships with Ultragenyx and Taysha Gene Therapies.
View full company profileTherapeutic Areas
Other Autosomal Dominant Optic Atrophy (ADOA) Drugs
| Drug | Company | Phase |
|---|---|---|
| TANGO ASO (Unnamed) | Stoke Therapeutics | Preclinical |